

Efficacy and safety of high-density lipoprotein cholesterol

Journal of the American College of Cardiology

45, 185-197

DOI: [10.1016/j.jacc.2004.10.031](https://doi.org/10.1016/j.jacc.2004.10.031)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Does raising high-density lipoprotein cholesterol level benefit patients with coronary artery disease?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 394-395.	3.3	0
2	HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Current Opinion in Lipidology, 2005, 16, 652-657.	1.2	5
5	Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: Comparison of the effects on morphological and biochemical parameters in liver and blood. European Journal of Drug Metabolism and Pharmacokinetics, 2005, 30, 203-218.	0.6	1
6	Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy, 2005, 19, 415-422.	1.3	21
8	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. British Journal of Diabetes and Vascular Disease, 2005, 5, S1-S15.	0.6	0
10	Beyond LDL-Cholesterol: HDL-Cholesterol as a Target for Atherosclerosis Prevention. Experimental and Clinical Endocrinology and Diabetes, 2005, 113, 414-417.	0.6	12
11	High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Current Medical Research and Opinion, 2005, 21, 1927-1934.	0.9	85
12	Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion, 2005, 21, 665-682.	0.9	99
13	The potential role of HDL and LDL cholesterol modulation in atheromatous plaque development. Current Medical Research and Opinion, 2005, 21, S17-S22.	0.9	14
15	Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 481-488.	2.0	5
16	Future strategies in the management of dyslipidemia. Future Cardiology, 2005, 1, 127-130.	0.5	0
17	Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets. Country Review Ukraine, 2005, 7, L16-L20.	0.8	1
18	Statins and LDL cholesterol lowering: an overview. Current Medical Research and Opinion, 2005, 21, S9-S16.	0.9	45
19	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 2005, 91, v1-v52.	1.2	731
20	Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology, 2005, 46, 1219-1224.	1.2	48
21	Controversies in stable coronary artery disease. Lancet, The, 2006, 367, 69-78.	6.3	56
22	LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. Atherosclerosis, 2006, 186, 1-11.	0.4	43
23	Is There Evidence for the Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women?. Gender Medicine, 2006, 3, 5-12.	1.4	0

#	ARTICLE	IF	CITATIONS
24	Antiatherogenic small, dense HDL“guardian angel of the arterial wall?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 144-153.	3.3	278
25	Fibrates after the FIELD study: some answers, more questions. Diabetes and Vascular Disease Research, 2006, 3, 166-171.	0.9	10
26	Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. Clinica Chimica Acta, 2006, 369, 168-178.	0.5	31
27	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. Current Therapeutic Research, 2006, 67, 321-333.	0.5	1
28	Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 121-127.	1.1	55
29	Favourable impact of low-calorie cranberry juice consumption on plasma HDL-cholesterol concentrations in men. British Journal of Nutrition, 2006, 96, 357-364.	1.2	111
30	Therapy and clinical trials: beyond low-density lipoprotein cholesterol reduction. Current Opinion in Lipidology, 2006, 17, 708-712.	1.2	0
31	Managing cholesterol in the elderly. Aging Health, 2006, 2, 623-638.	0.3	0
33	Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascular Diabetology, 2006, 5, 20.	2.7	72
34	FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice, 2006, 60, 442-449.	0.8	57
35	FIELD study. Diabetic Medicine, 2006, 23, 6-12.	1.2	1
36	Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International Journal of Clinical Practice, 2006, 60, 1697-1706.	0.8	35
37	Tratamiento de la hipertrigliceridemia: fibratos frente a Ácidos grasos omega-3. Revista Espanola De Cardiologia Suplementos, 2006, 6, 52D-61D.	0.2	6
38	Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. , 2006, 111, 893-908.		113
39	Lipid-lowering effects of statins: a comparative review. Expert Opinion on Pharmacotherapy, 2006, 7, 1701-1714.	0.9	47
40	Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diabetes and Vascular Disease Research, 2006, 3, S1-S12.	0.9	13
41	The Changing Face of Dyslipidemia Therapies. Journal of Pharmacy Practice, 2006, 19, 79-93.	0.5	0
42	The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases. Current Molecular Medicine, 2006, 6, 571-587.	0.6	49

#	ARTICLE	IF	CITATIONS
43	Tangier Disease Four Decades of Research: A Reflection of the Importance of HDL. <i>Current Medicinal Chemistry</i> , 2006, 13, 771-782.	1.2	55
44	Lipid-lowering therapy in type 2 diabetes: a review of the evidence. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, S10-S15.	0.9	0
45	Review: Fibrates: therapeutic review. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 11-19.	0.6	25
46	Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. <i>Future Cardiology</i> , 2006, 2, 635-646.	0.5	0
47	The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, S6-S9.	0.9	4
48	Cholesteryl Ester Transfer Protein Inhibition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 681-684.	1.1	19
49	Best practice in primary care pathology: review 7. <i>Journal of Clinical Pathology</i> , 2006, 60, 458-465.	1.0	11
50	Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. <i>European Heart Journal</i> , 2006, 28, 5-12.	1.0	46
51	Therapeutic use of the high-density lipoprotein protein and peptides. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 227-241.	1.9	8
52	Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. <i>Pharmacological Reviews</i> , 2006, 58, 342-374.	7.1	629
53	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	0.9	11
55	Update on advances in atherothrombosis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 78-89.	3.3	12
56	Validation of a questionnaire to assess niacin-induced cutaneous flushing. <i>Current Medical Research and Opinion</i> , 2007, 23, 1549-1560.	0.9	48
57	Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. <i>The American Heart Hospital Journal</i> , 2007, 5, 210-216.	0.2	4
58	Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol. <i>Archives of Internal Medicine</i> , 2007, 167, 999.	4.3	471
59	Atherosclerosis in type 2 diabetes: a role for fibrate therapy?. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 368-374.	0.9	22
61	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. <i>Journal of Lipid Research</i> , 2007, 48, 1763-1771.	2.0	86
62	The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 136-142.	0.9	36

#	ARTICLE	IF	CITATIONS
63	Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs. <i>Current Opinion in Lipidology</i> , 2007, 18, 613-621.	1.2	26
64	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
67	High-Density Lipoprotein Cholesterol: A Potential Therapeutic Target for Prevention of Coronary Artery Disease. <i>Preventive Cardiology</i> , 2007, 10, 26-30.	1.1	4
68	The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. <i>American Heart Journal</i> , 2007, 154, 943-953.	1.2	116
69	Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S23-S28.	1.1	6
70	Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. <i>Atherosclerosis</i> , 2007, 195, 385-391.	0.4	66
71	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2007, 9, 81-88.	2.0	10
72	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. <i>Future Lipidology</i> , 2007, 2, 285-301.	0.5	8
73	Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 618-626.	0.8	39
74	Chapter 12 Recent Trends in HDL Modulating Therapies. <i>Annual Reports in Medicinal Chemistry</i> , 2007, , 177-191.	0.5	2
76	Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2007, 357, 1009-1017.	13.9	259
77	Revisiting niacin: reviewing the evidence. <i>Journal of Clinical Lipidology</i> , 2007, 1, 248-255.	0.6	13
78	Recent trials of lipid lowering. <i>International Journal of Clinical Practice</i> , 2007, 61, 1145-1159.	0.8	13
79	HDL-c is a powerful lipid predictor of cardiovascular diseases. <i>International Journal of Clinical Practice</i> , 2007, 61, 1905-1913.	0.8	50
80	Clinical Significance of Recent Lipid Trials on Reducing Risk in Patients with Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 133-140.	0.7	20
81	Expert Commentary: Niacin Safety. <i>American Journal of Cardiology</i> , 2007, 99, S32-S34.	0.7	9
82	High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. <i>American Journal of Cardiology</i> , 2007, 100, S32-S40.	0.7	65
83	The role of CETP inhibition in dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2007, 9, 125-133.	2.0	13

#	ARTICLE	IF	CITATIONS
84	When high is low: Raising low levels of high-density lipoprotein cholesterol. <i>Current Cardiology Reports</i> , 2008, 10, 488-496.	1.3	13
85	Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2008, 24, 286-293.	1.7	17
86	Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?. <i>Advances in Cardiology</i> , 2008, 45, 127-153.	2.6	31
87	Safety of Niacin and Simvastatin Combination Therapy. <i>American Journal of Cardiology</i> , 2008, 101, S3-S8.	0.7	32
89	Cardiovascular Risk Factors. Insights From Framingham Heart Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2008, 61, 299-310.	0.4	112
90	High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2008, 51, 634-642.	1.2	330
91	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2016-2022.	1.1	161
92	HDL-C in post-menopausal women: An important therapeutic target. <i>International Journal of Cardiology</i> , 2008, 124, 275-282.	0.8	21
93	Synthetic HDL as a new treatment for atherosclerosis regression: Has the time come?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 329-335.	1.1	9
94	Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. <i>Clinical Therapeutics</i> , 2008, 30, 294-306.	1.1	26
95	Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema. <i>Clinical Therapeutics</i> , 2008, 30, 2314-2323.	1.1	46
96	Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. <i>Atherosclerosis</i> , 2008, 197, 710-717.	0.4	63
97	Effects of Niacin on Glucose Control in Patients With Dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2008, 83, 470-478.	1.4	101
98	L'acide nicotinique dans le traitement des dyslipidémies. <i>Medecine Des Maladies Metaboliques</i> , 2008, 2, 28-31.	0.1	0
99	Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?. <i>Cardiology Clinics</i> , 2008, 26, 537-546.	0.9	18
100	Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 419-427.	1.0	17
101	JTT-705: is there still future for a CETP inhibitor after torcetrapib?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1589-1597.	1.9	13
102	Advances in the management of hyperlipidemia-induced atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 369-383.	0.6	18

#	ARTICLE	IF	CITATIONS
103	Niacin: a lipid poly pill?. Expert Opinion on Pharmacotherapy, 2008, 9, 2911-2920.	0.9	7
104	Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism. PPAR Research, 2008, 2008, 1-11.	1.1	107
105	Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr <sup>-/-</sup> /ApoE <sup>-/-</sup> mice expressing CETP. Journal of Lipid Research, 2008, 49, 2113-2123.	2.0	6
106	Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Current Medical Research and Opinion, 2008, 24, 1817-1821.	0.9	17
107	Fibrates and future PPAR $\alpha$ agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 542-553.	3.3	141
108	D-Ribose Benefits Heart Failure Patients. Journal of Medicinal Food, 2008, 11, 199-200.	0.8	10
109	HDL Metabolism and CETP Inhibition. Cardiology in Review, 2008, 16, 154-162.	0.6	47
110	Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity. Current Pharmaceutical Design, 2008, 14, 574-587.	0.9	46
111	Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. Journal of Cardiovascular Pharmacology, 2008, 51, 331-351.	0.8	44
112	Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiologica, 2008, 63, 235-248.	0.3	7
113	The independent relationship between triglycerides and coronary heart disease. Vascular Health and Risk Management, 2008, , 89.	1.0	33
115	Therapies to Increase High-Density Lipoprotein Cholesterol and Their Effect on Cardiovascular Outcomes and Regression of Atherosclerosis. American Journal of the Medical Sciences, 2008, 336, 64-68.	0.4	10
116	Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management, 2008, Volume 4, 991-1000.	1.0	53
117	Nicotinic Acid. , 2009, , 298-314.		4
118	Raising HDL cholesterol in women. International Journal of Women's Health, 2009, 1, 181.	1.1	28
119	Combination Therapy for Dyslipidemia. , 2009, , 352-362.		1
120	Pharmacotherapy of coronary atherosclerosis. Expert Opinion on Pharmacotherapy, 2009, 10, 1587-1603.	0.9	26
121	Regulation of Bile Acid and Cholesterol Metabolism by PPARs. PPAR Research, 2009, 2009, 1-15.	1.1	150

#	ARTICLE	IF	CITATIONS
122	High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2009, 30, 1894-1902.	1.0	38
123	Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels. <i>Current Medicinal Chemistry</i> , 2009, 16, 144-156.	1.2	9
124	Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1336-1341.	1.1	39
125	Patients's experiences of niacin-induced flushing in clinical practice: A structured telephone interview. <i>Clinical Therapeutics</i> , 2009, 31, 130-140.	1.1	20
126	Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14). <i>American Journal of Cardiology</i> , 2009, 104, 234-239.	0.7	33
127	Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. <i>American Journal of Cardiology</i> , 2009, 104, 52E-57E.	0.7	23
128	More Clinical Lessons from the FIELD Study. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 235-241.	1.3	8
129	The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2009, 11, 329-333.	2.0	12
130	Managing diabetic dyslipidemia: Beyond statin therapy. <i>Current Diabetes Reports</i> , 2009, 9, 11-17.	1.7	19
131	Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. <i>Journal of Internal Medicine</i> , 2009, 265, 568-580.	2.7	183
132	Interpreting clinical trials of diabetic dyslipidaemia: new insights. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 261-270.	2.2	8
133	Combination statin-fibrate therapy: safety aspects. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 89-94.	2.2	59
134	The dual PPAR $\alpha/\beta$ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in <i>APOE*3Leiden.CETP</i> transgenic mice. <i>British Journal of Pharmacology</i> , 2009, 156, 1067-1075.	2.7	34
135	Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review. <i>American Journal of Medicine</i> , 2009, 122, 962.e1-962.e8.	0.6	106
136	Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. <i>New England Journal of Medicine</i> , 2009, 361, 2113-2122.	13.9	610
137	Lipid Management in the Geriatric Patient. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 185-206.	1.2	5
138	Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. <i>Atherosclerosis</i> , 2009, 202, 225-233.	0.4	22
139	Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controlled INEF study. <i>Atherosclerosis</i> , 2009, 204, 216-221.	0.4	77



#	ARTICLE	IF	CITATIONS
140	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	1.0	27
141	Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. <i>Current Opinion in Cardiology</i> , 2009, 24, 372-379.	0.8	31
142	Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study. <i>Current Pharmaceutical Design</i> , 2009, 15, 537-552.	0.9	71
143	Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. <i>Current Opinion in Cardiology</i> , 2009, 24, 473-482.	0.8	34
144	Targeting Dyslipidemia in the Metabolic Syndrome: An Update. <i>Current Vascular Pharmacology</i> , 2010, 8, 450-463.	0.8	8
145	High-Density Lipoprotein-Raising Strategies: Update 2010. <i>Current Pharmaceutical Design</i> , 2010, 16, 1517-1530.	0.9	14
147	Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. <i>Current Opinion in Cardiology</i> , 2010, 25, 603-608.	0.8	16
148	Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis. <i>American Journal of Therapeutics</i> , 2010, 17, e182-e188.	0.5	23
149	Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2010, 21, 352-358.	1.2	34
150	High-Density Lipoprotein Therapy: Is There Hope?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 315-328.	0.4	10
151	Management of the Patient with Statin Intolerance. <i>Current Atherosclerosis Reports</i> , 2010, 12, 48-57.	2.0	36
152	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
153	Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). <i>BMC Public Health</i> , 2010, 10, 737.	1.2	10
155	Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin. <i>International Journal of Pharmaceutics</i> , 2010, 400, 42-48.	2.6	9
156	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. <i>Vascular Health and Risk Management</i> , 2010, 6, 525.	1.0	44
157	Cholesterol-lowering phytosterols: factors affecting their use and efficacy. <i>Nutrition and Dietary Supplements</i> , 0, , 59.	0.7	29
158	Biochemical characterization of cholesteryl ester transfer protein inhibitors. <i>Journal of Lipid Research</i> , 2010, 51, 2739-2752.	2.0	92
159	Effects of Toremifene and Tamoxifen on Lipid Profiles in Post-menopausal Patients with Early Breast Cancer: Interim Results from a Japanese Phase III Trial. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 627-633.	0.6	19

#	ARTICLE	IF	CITATIONS
160	Fenofibrate and Metabolic Syndrome. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2010, 10, 138-148.	0.6	34
161	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. <i>European Heart Journal</i> , 2010, 31, 149-164.	1.0	256
162	The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. <i>Journal of Lipid Research</i> , 2010, 51, 2058-2073.	2.0	179
163	Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 731-738.	0.9	14
164	The Role of PPAR $\alpha$ Activation in Liver and Muscle. <i>PPAR Research</i> , 2010, 2010, 1-11.	1.1	124
165	Niacin's role in the statin era. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2291-2300.	0.9	13
166	A "Hot Topic in Dyslipidemia Management" – How to Beat a Flush: Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. <i>Mayo Clinic Proceedings</i> , 2010, 85, 365-379.	1.4	37
168	High-Density Lipoprotein and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1283-1299.	1.2	190
169	Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. <i>International Journal of Cardiology</i> , 2010, 141, 157-166.	0.8	48
170	A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 437-449.	1.9	9
171	Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. <i>Atherosclerosis</i> , 2010, 210, 353-361.	0.4	250
172	Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg. <i>Atherosclerosis</i> , 2010, 213, 235-240.	0.4	21
174	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. <i>Lancet</i> , The, 2010, 375, 1875-1884.	6.3	788
175	Utilization patterns of extended-release niacin in Canada: Analysis of an administrative claims database. <i>Canadian Journal of Cardiology</i> , 2010, 26, e229-e235.	0.8	11
176	Model-Based Meta-Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 766-769.	2.3	85
177	Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 424-427.	1.3	11
178	Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction. <i>Cardiology Clinics</i> , 2011, 29, 105-122.	0.9	10
179	HDL-cholesterol et approche thérapeutique. <i>Archives of Cardiovascular Diseases Supplements</i> , 2011, 3, 273-279.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2011, 31, 325-335.	1.1	18
182	Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. <i>Atherosclerosis</i> , 2011, 214, 422-425.	0.4	18
183	Pharmacologie et Thérapeutique Vasculaire. , 2011, , 687-843.		0
184	Nicotinic Acid Inhibits Glucose-Stimulated Insulin Secretion Via the G Protein-Coupled Receptor PUMA-G in Murine Islet $\beta^2$ Cells. <i>Pancreas</i> , 2011, 40, 615-621.	0.5	20
185	Adjunctive Lipid Lowering Therapy in the Era of Surrogate Endpoints. <i>Cardiology in Review</i> , 2011, 19, 17-22.	0.6	6
186	Cardiovascular screening: which populations, what measures of risk?. <i>International Journal of Clinical Practice</i> , 2011, 65, 3-5.	0.8	0
187	Niacin: the only vitamin that reduces cardiovascular events. <i>International Journal of Clinical Practice</i> , 2011, 65, 379-385.	0.8	27
188	Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1038-1044.	1.5	3
189	Efficacy and Tolerability of a New Extended-Release Formulation of Nicotinic Acid in Korean Adults With Mixed Dyslipidemia: An 8-Week, Multicenter, Prospective, Randomized, Double-Blind, and Placebo-Controlled Trial. <i>Clinical Therapeutics</i> , 2011, 33, 1357-1364.	1.1	7
190	Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 99-108.	1.9	17
191	Raising HDL-C through cholesteryl ester transfer protein inhibition. <i>Future Prescriber</i> , 2011, 12, 12-15.	0.1	0
192	Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors. <i>Annals of Pharmacotherapy</i> , 2011, 45, 84-94.	0.9	29
193	Vibrational spectroscopic investigation and normal coordinate analysis of the fibrate hypolipidemic agent 5-(2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid (Gemfibrozil). <i>Journal of Molecular Structure</i> , 2011, 990, 253-262.	1.8	9
194	The epidemiological concept of residual risk. <i>Internal and Emergency Medicine</i> , 2011, 6, 45-51.	1.0	30
195	Familial Hypercholesterolemia: Present and Future Management. <i>Current Cardiology Reports</i> , 2011, 13, 527-536.	1.3	40
196	Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. <i>Lipids in Health and Disease</i> , 2011, 10, 212.	1.2	4
197	Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. <i>BMC Medicine</i> , 2011, 9, 74.	2.3	46
198	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <i>Clinical Lipidology</i> , 2011, 6, 181-208.	0.4	9

#	ARTICLE	IF	CITATIONS
199	Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Peritoneal Dialysis International, 2011, 31, 218-239.	1.1	97
200	Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products. Postgraduate Medicine, 2011, 123, 70-83.	0.9	12
201	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2011, 12, 1429-1438.	0.9	16
203	Lipid-lowering Drug Therapy in Elderly Patients. Current Pharmaceutical Design, 2011, 17, 877-893.	0.9	29
204	Hyperlipidemia in Primary Care. , 2011, , .		2
205	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs, 2011, 16, 203-233.	1.0	1
206	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opinion on Pharmacotherapy, 2011, 12, 13-30.	0.9	59
207	Acute renal failure due to fenofibrate monotherapy. Anatolian Journal of Cardiology, 2011, 11, 371-2.	0.4	1
208	Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs. Annals of Clinical Biochemistry, 2011, 48, 3-4.	0.8	1
209	Triglycerides. Current Opinion in Cardiology, 2012, 27, 398-404.	0.8	32
210	Niacinâ€”A Critical Component to the Management of Atherosclerosis. Journal of Cardiovascular Nursing, 2012, 27, 303-316.	0.6	2
211	Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review. Postgraduate Medicine, 2012, 124, 7-20.	0.9	11
212	Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs, 2012, 21, 1427-1432.	1.9	17
213	Elevation of Plasma High-Density Lipoproteins Inhibits Development of Experimental Abdominal Aortic Aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2678-2686.	1.1	33
214	Evaluation of Î±-D-ribofuranose (D-ribose) toxicity after intravenous administration to rabbits. Human and Experimental Toxicology, 2012, 31, 820-829.	1.1	3
215	Safety and tolerability of extended-release niacin with laropiprant. Expert Opinion on Drug Safety, 2012, 11, 151-159.	1.0	6
216	The Effect of CYP7A1 Polymorphisms on Lipid Responses to Fenofibrate. Journal of Cardiovascular Pharmacology, 2012, 59, 254-259.	0.8	23
218	Lipid-Lowering Drugs and Circulating Adiponectin. Vitamins and Hormones, 2012, 90, 341-374.	0.7	11

#	ARTICLE	IF	CITATIONS
219	Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6503-6508.	1.0	18
220	Triglycerides: How Much Credit Do They Deserve?. <i>Medical Clinics of North America</i> , 2012, 96, 39-55.	1.1	16
221	Extended-release niacin with laropirant: a review on efficacy, clinical effectiveness and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1345-1362.	0.9	24
222	Niacin: another look at an underutilized lipid-lowering medication. <i>Nature Reviews Endocrinology</i> , 2012, 8, 517-528.	4.3	41
223	Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 348-354.	1.1	89
224	Extended-release Niacin Acutely Suppresses Postprandial Triglyceridemia. <i>American Journal of Medicine</i> , 2012, 125, 1026-1035.	0.6	20
225	Novel LDL-oriented pharmacotherapeutical strategies. <i>Pharmacological Research</i> , 2012, 65, 402-410.	3.1	3
226	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	5.3	187
228	Diabetic Nephropathy: A Cardiovascular Risk Factor. , 0, , .		0
229	Mixed dyslipidemias in primary care patients in France. <i>Vascular Health and Risk Management</i> , 2012, 8, 247.	1.0	14
230	Hypercholesterolaemia: what to do when first-line treatment fails. <i>The Prescriber</i> , 2012, 23, 28-33.	0.1	0
231	Anacetrapib, a cholesteryl ester transfer protein inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 103-109.	1.9	9
232	Attainment of Normal Lipid Levels Among Patients on Lipid-Modifying Therapy in Hong Kong. <i>Advances in Therapy</i> , 2012, 29, 427-441.	1.3	6
233	New lipid-lowering drugs: an update. <i>International Journal of Clinical Practice</i> , 2012, 66, 270-280.	0.8	61
234	Niacin: The Evidence, Clinical Use, and Future Directions. <i>Current Atherosclerosis Reports</i> , 2012, 14, 49-59.	2.0	34
235	Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 102-107.	0.8	1
236	Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. <i>Journal of Cardiothoracic Surgery</i> , 2013, 8, 172.	0.4	11
237	The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1840-1849.	1.5	7

#	ARTICLE	IF	CITATIONS
238	How to control residual cardiovascular risk despite statin treatment: Focusing on HDL cholesterol. <i>International Journal of Cardiology</i> , 2013, 166, 8-14.	0.8	54
240	Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. <i>European Journal of Internal Medicine</i> , 2013, 24, 656-663.	1.0	7
241	Lipids in Women. , 2013, , 965-974.		0
242	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. <i>Current Cardiology Reports</i> , 2013, 15, 391.	1.3	9
243	Epanova <sup>®</sup> and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. <i>Future Cardiology</i> , 2013, 9, 177-186.	0.5	12
244	Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia. <i>Clinical Therapeutics</i> , 2013, 35, 450-460.	1.1	1
245	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. <i>European Heart Journal</i> , 2013, 34, 1279-1291.	1.0	581
246	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. <i>Journal of Lipid Research</i> , 2013, 54, 1980-1987.	2.0	7
247	High-density lipoprotein cholesterol raising. <i>Current Opinion in Cardiology</i> , 2013, 28, 464-474.	0.8	21
248	Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 1201-1209.	2.2	90
249	Sex-Specific Differences in Type 2 Diabetes Mellitus and Dyslipidemia Therapy: PPAR Agonists. <i>Handbook of Experimental Pharmacology</i> , 2013, , 387-410.	0.9	24
250	Niacin, an old drug with a new twist. <i>Journal of Lipid Research</i> , 2013, 54, 2586-2594.	2.0	44
251	New insights into the molecular mechanism of intestinal fatty acid absorption. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1203-1223.	1.7	151
252	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. <i>Vascular Health and Risk Management</i> , 2013, 9, 671.	1.0	28
253	Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e77049.	1.1	28
254	Dyslipidaemia: what's around the corner?. <i>Clinical Medicine</i> , 2014, 14, s41-s44.	0.8	5
255	APOE <sup>3</sup> Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 537-544.	2.2	42
256	Lipid-Lowering Drugs Associated With Slower Motor Decline in the Elderly Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 199-206.	1.7	20

#	ARTICLE	IF	CITATIONS
257	Recent advances in physiological lipoprotein metabolism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1695-727.	1.4	167
258	Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 669-674.	1.9	21
259	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	2.2	61
260	Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, 142, 375-415.		437
261	Anti-hypercholesterolemic effect of Pistacia lentiscus fatty oil in egg yolk-fed rabbits: a comparative study with simvastatin. <i>Chinese Journal of Natural Medicines</i> , 2014, 12, 561-566.	0.7	24
262	Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 192-205.	2.3	20
263	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
264	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.4	39
265	Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 361-377.	1.3	42
266	Effects of CP-900691, a novel peroxisome proliferator-activated receptor $\alpha$ agonist on diabetic nephropathy in the BTBR ob/ob mouse. <i>Laboratory Investigation</i> , 2014, 94, 851-862.	1.7	9
268	A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 455-459.	0.6	7
269	Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. <i>Hepatology</i> , 2015, 62, 1710-1722.	3.6	60
270	A Grape Seed Procyanidin Extract Ameliorates Fructose-Induced Hypertriglyceridemia in Rats via Enhanced Fecal Bile Acid and Cholesterol Excretion and Inhibition of Hepatic Lipogenesis. <i>PLoS ONE</i> , 2015, 10, e0140267.	1.1	30
271	Lipid abnormalities in kidney disease and management strategies. <i>World Journal of Nephrology</i> , 2015, 4, 83.	0.8	43
272	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 43.	2.0	27
273	Secondary Prevention After Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2015, 131, 927-964.	1.6	313
275	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature. <i>Atherosclerosis</i> , 2015, 242, 647-656.	0.4	56
276	Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. <i>Journal of Clinical Lipidology</i> , 2015, 9, 313-325.	0.6	11



#	ARTICLE	IF	CITATIONS
278	Synthesis and biological evaluation of isoflavone amide derivatives with antihyperlipidemic and preadipocyte antiproliferative activities. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4428-4433.	1.4	3
279	Indicators of hypertriglyceridemia from anthropometric measures based on data mining. <i>Computers in Biology and Medicine</i> , 2015, 57, 201-211.	3.9	12
280	NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. <i>Cell Metabolism</i> , 2015, 22, 31-53.	7.2	1,153
281	Statins and Niacin: The End of Residual Risk Therapy?. , 2015, , 37-43.		2
282	Nonstatin Therapies for Management of Dyslipidemia: A Review. <i>Clinical Therapeutics</i> , 2015, 37, 2153-2179.	1.1	39
283	Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. <i>Geriatrics and Gerontology International</i> , 2015, 15, 302-310.	0.7	21
284	Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials. <i>Clinical Nutrition</i> , 2015, 34, 838-844.	2.3	26
286	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. , 0, , .		1
287	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 282-303.	0.7	13
288	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	1.0	166
289	Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 145-149.	1.2	10
290	Studies on the regulation of lipid metabolism and its mechanism of the iridoids rich fraction in <i>Valeriana jatamansi</i> Jones. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1891-1898.	2.5	21
291	Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management. <i>Archives of Medical Research</i> , 2016, 47, 491-495.	1.5	27
292	Diabetes Dyslipidemia. <i>Diabetes Therapy</i> , 2016, 7, 203-219.	1.2	259
293	Statin combination therapy and cardiovascular risk reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	0.5	13
294	Olive oil, compared to a saturated dietary fat, has a protective role on atherosclerosis in niacin-treated mice with metabolic syndrome. <i>Journal of Functional Foods</i> , 2016, 26, 557-564.	1.6	8
295	Pleiotropic effects of niacin: Current possibilities for its clinical use. <i>Acta Pharmaceutica</i> , 2016, 66, 449-469.	0.9	21
296	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 216-228.	1.0	8



#	ARTICLE	IF	CITATIONS
297	Niacin: old habits die hard. <i>Heart</i> , 2016, 102, 170-171.	1.2	1
298	Nicorandil, Gastrointestinal Adverse Drug Reactions and Ulcerations: A Systematic Review. <i>Advances in Therapy</i> , 2016, 33, 320-344.	1.3	13
299	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 285-294.	1.1	17
300	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. <i>Current Atherosclerosis Reports</i> , 2016, 18, 17.	2.0	23
301	Management of residual risk after statin therapy. <i>Atherosclerosis</i> , 2016, 245, 161-170.	0.4	71
302	Beneficial effects of cranberry in the prevention of obesity and related complications: Metabolic syndrome and diabetes – A review. <i>Journal of Functional Foods</i> , 2016, 20, 171-181.	1.6	47
303	Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. <i>Journal of Lipid Research</i> , 2017, 58, 783-797.	2.0	5
304	Mechanistic insight into nuclear receptor-mediated regulation of bile acid metabolism and lipid homeostasis by grape seed procyanidin extract (GSPE). <i>Cell Biochemistry and Function</i> , 2017, 35, 12-32.	1.4	21
305	Treatment of Lipid Metabolism Disturbances in Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 169-182.	0.1	0
306	Adipose tissue NAD <sup>+</sup> -homeostasis, sirtuins and poly(ADP-ribose) polymerases -important players in mitochondrial metabolism and metabolic health. <i>Redox Biology</i> , 2017, 12, 246-263.	3.9	78
307	Extended-release niacin increases anti-apolipoprotein A antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1002-1010.	1.1	20
308	Niacin for primary and secondary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD009744.	1.5	43
309	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). <i>Journal of Clinical Lipidology</i> , 2017, 11, 872-879.	0.6	9
310	Nuclear Receptors and the Adaptive Response of the Heart. , 2017, , 249-284.		0
311	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German <sc>DIVE</sc> and <sc>DPV</sc> registries. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 61-69.	2.2	9
312	Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. <i>Cell Metabolism</i> , 2018, 27, 529-547.	7.2	565
313	Clinical and Vitamin Response to a Short-Term Multi-Micronutrient Intervention in Brazilian Children and Teens: From Population Data to Interindividual Responses. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1700613.	1.5	27
314	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 197-205.	1.1	34

#	ARTICLE	IF	CITATIONS
316	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 51-69.	0.7	8
317	Benefits and risks of the treatment with fibrates—a comprehensive summary. Expert Review of Clinical Pharmacology, 2018, 11, 1099-1112.	1.3	34
318	High-Density Lipoproteins-Associated Proteins and Subspecies Related to Arterial Stiffness in Young Adults with Type 2 Diabetes Mellitus. Complexity, 2018, 2018, 1-14.	0.9	0
319	Genetic and Epigenetic Regulations of Post-prandial Lipemia. Current Genetic Medicine Reports, 2018, 6, 124-131.	1.9	0
320	Management of Hypertriglyceridemia Induced Acute Pancreatitis. BioMed Research International, 2018, 2018, 1-12.	0.9	124
321	Nutritional Regulation of Mitochondrial Function. , 2019, , 93-126.		5
322	Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes. JAMA Network Open, 2019, 2, e192224.	2.8	49
323	The APOE <sup>ε4</sup> 3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis. Journal of Diabetes Research, 2019, 2019, 1-13.	1.0	8
324	NAD <sup>+</sup> metabolism as a target for metabolic health: have we found the silver bullet?. Diabetologia, 2019, 62, 888-899.	2.9	47
325	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy, 2019, 8, 5-20.	1.1	17
326	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 533-543.	0.8	42
327	Management of Dyslipidemia. Contemporary Cardiology, 2019, , 39-69.	0.0	0
328	Impact of multi-micronutrient supplementation on lipidemia of children and adolescents. Clinical Nutrition, 2020, 39, 2211-2219.	2.3	8
329	Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. Archives of Cardiovascular Diseases, 2020, 113, 617-629.	0.7	3
330	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Advanced Drug Delivery Reviews, 2020, 159, 54-93.	6.6	18
331	Rate of inappropriate energy and micronutrient intake among the Korean working population. Public Health Nutrition, 2020, 23, 3356-3367.	1.1	2
332	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Expert Review of Cardiovascular Therapy, 2020, 18, 175-180.	0.6	8
333	Effects of Bariatric Surgery on HDL Cholesterol. Obesity Surgery, 2020, 30, 1793-1798.	1.1	11

#	ARTICLE	IF	CITATIONS
334	Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. <i>Trials</i> , 2020, 21, 353.	0.7	2
335	Cholesterol Trafficking in the Brain. <i>Neurology</i> , 2021, 96, 465-466.	1.5	1
336	Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study. <i>Lipids in Health and Disease</i> , 2021, 20, 17.	1.2	11
337	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	1.2	49
338	Triglycerides and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 469-477.	0.8	19
339	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2233.	1.0	15
342	Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 593-615.	0.9	22
343	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4
345	HDL cholesterol and cardiovascular risk. <i>BMJ: British Medical Journal</i> , 2009, 338, a3065-a3065.	2.4	11
346	Seeing red: flushing out instigators of niacin-associated skin toxicity. <i>Journal of Clinical Investigation</i> , 2010, 120, 2651-2655.	3.9	30
347	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. <i>PLoS ONE</i> , 2013, 8, e66467.	1.1	36
348	Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2014, 9, e94585.	1.1	66
349	Lipoproteínas de alta densidade: aspectos metabólicos, clínicos, epidemiológicos e de intervenção terapêutica. <i>Atualizações para os clínicos. Arquivos Brasileiros De Cardiologia</i> , 2006, 87, 671-679.	0.3	22
350	Cardioprotective Properties of HDL: Structural and Functional Considerations. <i>Current Medicinal Chemistry</i> , 2020, 27, 2964-2978.	1.2	19
351	Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. <i>Future Lipidology</i> , 2006, 1, 47-54.	0.5	1
352	Role of niacin in current clinical practice. <i>Minerva Medica</i> , 2019, 110, 79-83.	0.3	8
353	High-Density Lipoprotein Cholesterol. , 2016, , 321-366.		2
354	High-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006, , 295-340.	0.0	2

#	ARTICLE	IF	CITATIONS
355	National Cholesterol Education Panel III performance in preventing myocardial infarction in young adults. <i>Annals of Saudi Medicine</i> , 2008, 28, 22-27.	0.5	5
356	Therapeutic management of hyperlipoproteinemia (a). <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	14
357	Triglycerides and Risk for Atherosclerotic Disease. <i>Fundamental and Clinical Cardiology</i> , 2006, , 341-388.	0.0	0
358	Congestive Heart Failure and Cardiomyopathy. , 2009, , .		0
359	Wat is belangrijker: een hoog HDL of een laag LDL?. , 2010, , 48-54.		0
360	2 Premature atherosclerose. , 2010, , 41-48.		0
361	Genetic Disorders of the Lipoprotein Metabolism; Diagnosis and Management. , 2011, , 305-330.		0
362	Isolated Low HDL. , 2011, , 159-171.		0
364	Lipid management after a coronary event. , 2011, , 328-337.		0
365	Safety, Tolerability and Pharmacokinetics of Dalcatrapib Following Single and Multiple Ascending Doses in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2011, , 1.	1.1	0
368	High-Density Lipoprotein as a Therapeutic Target: Treatment Strategies. <i>Cardiovascular Journal</i> , 2012, 5, 73-80.	0.0	0
370	Diabetes and the Cardiovascular System. , 2013, , 701-714.		0
371	Increased Serum Cholesteryl Ester Transfer Protein in Syrian Obese Humans. <i>Gazi Medical Journal</i> , 0, , .	0.3	0
372	Study of Coronary Risk Factors in Rural Malaysia Population. <i>International Journal of Medical Biology</i> , 2015, 2, 1-7.	0.0	1
373	Fibra diettica e gordura saturada: relao entre marcadores bioqumicos da sndrome metablica. <i>Scientia Medica</i> , 2015, 25, 18236.	0.1	0
374	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2016, , 331-354.		0
375	An Update on Hypertriglyceridemia-Induced Acute Pancreatitis. <i>Korean Journal of Medicine</i> , 2018, 93, 518-524.	0.1	0
376	Regulation of NAD+ metabolism in aging and disease. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154923.	1.5	40

#	ARTICLE	IF	CITATIONS
377	Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). Contemporary Cardiology, 2021, , 295-306.	0.0	1
378	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
379	Effect of Oxygen on Adipose Tissue Inflammation - A Randomized, Placebo-Controlled Clinical Study. International Journal of Physical Education Fitness and Sports, 0, , 37-50.	0.2	1
380	The independent relationship between triglycerides and coronary heart disease. Vascular Health and Risk Management, 2009, 5, 89-95.	1.0	54
381	Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study. Cardiovascular Journal of Africa, 2008, 19, 97-101.	0.2	6
382	Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. Indian Journal of Medical Research, 2013, 138, 873-81.	0.4	1
384	Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals. Molecular Nutrition and Food Research, 2021, , 2100192.	1.5	3
385	Outcome-Based Reimbursement: The Solution to High Drug Spending?. Manufacturing and Service Operations Management, 2022, 24, 2029-2047.	2.3	7
386	Triglycerides. Medical Clinics of North America, 2022, 106, 299-312.	1.1	2
388	Lipid Lowering Therapy: An Era Beyond Statins. Current Problems in Cardiology, 2022, 47, 101342.	1.1	24
389	Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	17
390	Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	0
391	Dietary niacin intake and risk of dyslipidemia: A pooled analysis of three prospective cohort studies. Clinical Nutrition, 2022, 41, 2749-2758.	2.3	3
392	Comparison of the effects of triglyceride variability and exposure estimate on clinical prognosis in diabetic patients. Cardiovascular Diabetology, 2022, 21, .	2.7	2
393	NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease. Cells, 2023, 12, 21.	1.8	4
394	Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis. International Journal of Molecular Sciences, 2022, 23, 16224.	1.8	6
395	Very low HDL levels: clinical assessment and management. Archives of Endocrinology and Metabolism, 2023, 67, 3-18.	0.3	4
396	Biochemical, Clinical, and Genetic Characteristics of Mexican Patients with Primary Hypertriglyceridemia, Including the First Case of Hyperchylomicronemia Syndrome Due to GPIIIBP1 Deficiency. International Journal of Molecular Sciences, 2023, 24, 465.	1.8	0

#	ARTICLE	IF	CITATIONS
397	Antihypercholesterolemic effects of Hemp ( <i>Cannabis sativa</i> ). , 2023, , 427-440.		0